MUMBAI, India, Feb. 13 -- Intellectual Property India has published a patent application (202541133302 A) filed by Dr. Chandrashekhar V. M; Malllkarjun Sunkad; Lingaraj Veerabhadrappa Anwal; Sanjay Chanabasappa Havaragi; Dr. Mallappa Shalavadi; and Dr. Prashant Yuvaraj Mali, Bagalkote, Karnataka, on Dec. 30, 2025, for 'novel formulation of gossypin nano suspension for the treatment of lung fibrosis.'
Inventor(s) include Dr. Chandrashekhar V. M; Malllkarjun Sunkad; Lingaraj Veerabhadrappa Anwal; Sanjay Chanabasappa Havaragi; Dr. Mallappa Shalavadi; and Dr. Prashant Yuvaraj Mali.
The application for the patent was published on Feb. 13, under issue no. 07/2026.
According to the abstract released by the Intellectual Property India: "The present invention reveals a novel formulation of gossypin nano suspension for the treatment of lung fibrosis thereof. More particularly, the invention relates to the preparation of novel gossypin nano suspension formulation by solvent evaporation technique. The invention also involves characterization of novel gossypin nano suspension formulation by particle size, poly dispersity index and zeta potential. The invention encompasses the pre-clinical experimental effects of novel gossypin ' nano suspension formulation and 5-nuorouracil as a standard drug for the treatment of bleomycin induced lung fibrosis in Sprague Dawley rats by considering different parameters such as Lung index assay. Antioxidant enzyme activities / biochemical marker assays like Glutathione (GSH), Superoxide dismutase (SOD), Lipid peroxidation (LPO) and Catalase (CAT) and histopathological assessments."
Disclaimer: Curated by HT Syndication.
